Direct-to-Consumer Drug Advertising in Oncology Is Not Beneficial to Patients or Public Health

JAMA Oncol. 2016 Nov 1;2(11):1397-1398. doi: 10.1001/jamaoncol.2016.2463.

Authors

Lowell E Schnipper¹, Gregory A Abel²

Affiliations

¹ Division of Hematology-Oncology and Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
² Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

PMID: 27532895
DOI: 10.1001/jamaoncol.2016.2463

No abstract available

MeSH terms

Antineoplastic Agents* / adverse effects
Antineoplastic Agents* / economics
Antineoplastic Agents* / therapeutic use
Direct-to-Consumer Advertising
Drug Industry / organization & administration
Humans
Information Dissemination
Neoplasms / drug therapy*
United States
United States Food and Drug Administration

Substances

Antineoplastic Agents